143 related articles for article (PubMed ID: 32020229)
21. Cell Cycle Regulation by Berberine in Human Melanoma A375 Cells.
Ren M; Yang L; Li D; Yang L; Su Y; Su X
Bull Exp Biol Med; 2020 Aug; 169(4):491-496. PubMed ID: 32915362
[TBL] [Abstract][Full Text] [Related]
22. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.
Avery-Kiejda KA; Zhang XD; Adams LJ; Scott RJ; Vojtesek B; Lane DP; Hersey P
Clin Cancer Res; 2008 Mar; 14(6):1659-68. PubMed ID: 18310316
[TBL] [Abstract][Full Text] [Related]
23. Cyclin F-dependent degradation of E2F7 is critical for DNA repair and G2-phase progression.
Yuan R; Liu Q; Segeren HA; Yuniati L; Guardavaccaro D; Lebbink RJ; Westendorp B; de Bruin A
EMBO J; 2019 Oct; 38(20):e101430. PubMed ID: 31475738
[TBL] [Abstract][Full Text] [Related]
24. FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression.
Ishitsuka A; Fujine E; Mizutani Y; Tawada C; Kanoh H; Banno Y; Seishima M
Int J Mol Med; 2014 Oct; 34(4):1169-74. PubMed ID: 25109763
[TBL] [Abstract][Full Text] [Related]
25. Macrovipecetin, a C-type lectin from Macrovipera lebetina venom, inhibits proliferation migration and invasion of SK-MEL-28 human melanoma cells and enhances their sensitivity to cisplatin.
Hammouda MB; Riahi-Chebbi I; Souid S; Othman H; Aloui Z; Srairi-Abid N; Karoui H; Gasmi A; Magnenat EM; Wells TNC; Clemetson KJ; Rodríguez-López JN; Essafi-Benkhadir K
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):600-614. PubMed ID: 29196192
[TBL] [Abstract][Full Text] [Related]
26. Skp2 regulates G2/M progression in a p53-dependent manner.
Hu R; Aplin AE
Mol Biol Cell; 2008 Nov; 19(11):4602-10. PubMed ID: 18716061
[TBL] [Abstract][Full Text] [Related]
27. Ribonucleotide reductase small subunit M2 is a master driver of aggressive prostate cancer.
Mazzu YZ; Armenia J; Nandakumar S; Chakraborty G; Yoshikawa Y; Jehane LE; Lee GM; Atiq M; Khan N; Schultz N; Kantoff PW
Mol Oncol; 2020 Aug; 14(8):1881-1897. PubMed ID: 32385899
[TBL] [Abstract][Full Text] [Related]
28. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
29. Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance.
Li W; Melton DW
Oncogene; 2012 May; 31(19):2412-22. PubMed ID: 21996734
[TBL] [Abstract][Full Text] [Related]
30. WP1130 attenuates cisplatin resistance by decreasing P53 expression in non-small cell lung carcinomas.
Wang X; Bao Y; Dong Z; Chen Q; Guo H; Ziang C; Shao J
Oncotarget; 2017 Jul; 8(30):49033-49043. PubMed ID: 28446729
[TBL] [Abstract][Full Text] [Related]
31. Increased cytotoxicity of cisplatin in SK-MEL 28 melanoma cells upon down-regulation of melanoma inhibitor of apoptosis protein.
Mousavi-Shafaei P; Ziaee AA; Zangemeister-Wittke U
Iran Biomed J; 2009 Jan; 13(1):27-34. PubMed ID: 19252675
[TBL] [Abstract][Full Text] [Related]
32. Identification of genes associated with cisplatin resistance in human oral squamous cell carcinoma cell line.
Zhang P; Zhang Z; Zhou X; Qiu W; Chen F; Chen W
BMC Cancer; 2006 Sep; 6():224. PubMed ID: 16978399
[TBL] [Abstract][Full Text] [Related]
33. Casein kinase II phosphorylation of cyclin F at serine 621 regulates the Lys48-ubiquitylation E3 ligase activity of the SCF
Lee A; Rayner SL; De Luca A; Gwee SSL; Morsch M; Sundaramoorthy V; Shahheydari H; Ragagnin A; Shi B; Yang S; Williams KL; Don EK; Walker AK; Zhang KY; Yerbury JJ; Cole NJ; Atkin JD; Blair IP; Molloy MP; Chung RS
Open Biol; 2017 Oct; 7(10):. PubMed ID: 29021214
[TBL] [Abstract][Full Text] [Related]
34. SCYL1-BP1 affects cell cycle arrest in human hepatocellular carcinoma cells via Cyclin F and RRM2.
Wang Y; Zhi Q; Ye Q; Zhou C; Zhang L; Yan W; Wu Q; Zhang D; Li P; Huo K
Anticancer Agents Med Chem; 2016; 16(4):440-6. PubMed ID: 25980818
[TBL] [Abstract][Full Text] [Related]
35. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
36. Identification of osalmid metabolic profile and active metabolites with anti-tumor activity in human hepatocellular carcinoma cells.
Wu Z; Zhan Y; Wang L; Tong J; Zhang L; Lin M; Jin X; Jiang L; Lou Y; Qiu Y
Biomed Pharmacother; 2020 Oct; 130():110556. PubMed ID: 32763815
[TBL] [Abstract][Full Text] [Related]
37. Low molecular weight heparin ablates lung cancer cisplatin-resistance by inducing proteasome-mediated ABCG2 protein degradation.
Niu Q; Wang W; Li Y; Ruden DM; Wang F; Li Y; Wang F; Song J; Zheng K
PLoS One; 2012; 7(7):e41035. PubMed ID: 22844424
[TBL] [Abstract][Full Text] [Related]
38. Modulation of chemoresistance by lysophosphatidic acid (LPA) signaling through LPA
Minami K; Ueda N; Maeda H; Ishimoto K; Otagaki S; Tsujiuchi T
Biochem Biophys Res Commun; 2019 Sep; 517(2):359-363. PubMed ID: 31362892
[TBL] [Abstract][Full Text] [Related]
39. Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin.
Bérubé M; Talbot M; Collin C; Paquet-Bouchard C; Germain L; Guérin SL; Petitclerc E
Int J Oncol; 2005 Feb; 26(2):405-13. PubMed ID: 15645125
[TBL] [Abstract][Full Text] [Related]
40. Anticancer properties of chitosan on human melanoma are cell line dependent.
Gibot L; Chabaud S; Bouhout S; Bolduc S; Auger FA; Moulin VJ
Int J Biol Macromol; 2015 Jan; 72():370-9. PubMed ID: 25193096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
